Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Angi Inc (ANGI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Angi Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Angi Inc trades at $6.14 (market cap $260.08M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 17.3× Angi Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Angi Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | ANGI | |
|---|---|---|
Market Cap | $4.49B | $260.08M |
Sector | Health | Media |
52-Week High | $28.06 | $18.90 |
52-Week Low | $20.06 | $4.78 |
Enterprise Value | $3.69B | $486.89M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ANGI trades at $6.44, up 6.27% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue declined to $1.03B in 2025, though net income improved to $43.83M. Valuation ratios appear low with P/E of 14.86 and P/S of 0.27. Recent news highlights an AI strategy pivot and multiple law firm fraud investigations, creating uncertainty.
The stock offers potential upside to the $9.20 consensus price target, but risks include declining revenue, negative cash flows, and legal scrutiny. Analyst sentiment is cautious with 62.97% hold ratings. Execution of the AI transition and resolution of legal issues are critical for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Angi Inc
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie's List, Handy, mHelpDesk, HomeStars, and Fixd Repair
Read more on ANGI →
